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Abstract
Background
High risk human papillomavirus (hr-HPV) infection and the dual burden of HIV remains a
huge challenge in some low-income countries (LICs) such as Swaziland with limited or no
data. We estimated the prevalence and investigated determinants of hr-HPV, including HIV
infection among sexually active women in Swaziland.
Methods
A total of 655 women aged between 15 and 49 years from five health facilities were ran-
domly enrolled using a cross-sectional study design. Cervical cells were tested for hr-HPV
types using GeneXpert HPV Assays.
Results
The overall weighted hr-HPV prevalence was 46.2% (95%CI: 42.8–49.5). Of hr-HPV
infected women, 12.4% (95%CI: 8.6–17.5) were HPV16-positive, 13.8% (95%CI:12.0–
15.8) were positive for HPV18/45, 26.7% (95%CI: 24.2–29.3) for HPV31/33/35/52/58, 7.6%
(95%CI: 7.6–11.9) for HPV51/59 and 11.0%, (95%CI: 7.9–15.3) for HPV39/56/66/68. Prev-
alence of hr-HPV decreased with increasing age. Overall HIV prevalence remained high
(42.7%; 95%CI: 35.7–46.2). HIV infection was associated with hr-HPV infection (Adjusted
OR = 4.9, 95%CI: 3.043–7.8, p<0.001). Overall hr-HPV/HIV co-infection was 24.4% (95%
CI: 20.3–29.1) which was significantly higher among younger age groups (p<0.001). Preva-
lence of multiple group hr-HPV infection was significantly higher in HIV-positive versus
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-negative women (27.7% and 12.7% respectively, p<0.001). The presence, absence or
unknown of history of STI with HIV did not appear to modify the relationship with hr-HPV
(OR = 4.2, 95%CI: 2.6–7.1, OR = 4.6, 95%CI: 2.8–7.7, p<0.001, p<0.001 and OR = 4.1,
95%CI: 1.3–13.4, p<0.021 respectively).
Conclusion
The prevalence of hr-HPV infection was high and significantly associated with HIV among
sexually active women. Furthermore, the study has provided essential information about the
HIV link with hr-HPV infections which may explain the high prevalence among HIV infected
women. This can contribute to policy development and planning of prevention strategies
incorporating HPV infection prevention especially among youth and HIV infected people.
Introduction
In low-income countries (LICs), the burden of cervical cancer is a serious health problem and
predominantly affects women of reproductive age [1]. Cervical cancer (CC) is the fourth most
common cancer, and about (87%) of cases occurred in LICs in 2012 [2]. Out of the 40 Human
Papillomavirus (HPV) genotypes that infect the genital tract, 13 are considered to be "high-
risk" and approximately 80% of women worldwide become infected with at least one type
before reaching 50 years [3]. High risk HPV (hr-HPV) is the major and necessary cause of CC
[4]. HPV16 and 18 are associated with approximately 71% of all cases of CC, and HPV45 is
associated with approximately 6% of additional cases of CC [5]. The prevalence of HPV infec-
tion in women varies greatly in the African continent where some of the highest prevalences
are found [6]. Both hr-HPV and HIV are sexually transmitted infectious agents, and infection
by one of the viruses may accelerate transmission of the other [7]. The impact of co-infection
of HPV with HIV in the Sub-Saharan African countries has created a huge burden of cervical
abnormalities since HIV infected women have higher prevalence of hr-HPV [8]. The latter is
more likely to be persistent in HIV-infected women, and results in a higher incidence of high-
grade squamous intraepithelial lesion (HSIL) [9].
The high prevalence of HPV infection among women in several African countries may be
explained by the presence of risk factors such as early age sexual debut, the number of sexual
partners of women and of their partners, and other STIs, including HIV, as discussed above
[10–13]. Previous studies have shown that the prevalence of HPV infection rises soon after the
onset of sexual activity [14, 15] and peaks in adolescence and early adulthood after which it
declines during later decades of life [16]. The high prevalence of HPV infection among young
women has been found to be due to the absence of adaptive immune response and the rela-
tively larger area of cervical epithelium undergoing squamous metaplasia [17].
Studies estimating HPV infection are limited in African countries [4]. The lack of hr-HPV
identification for CC screening has delayed the improving and expansion of triage, treatment
and prevention in LICs like Swaziland. Information on country-specific HPV genotype preva-
lence is needed to inform local policy, screening and prevention programmes. Randomised tri-
als have demonstrated that HPV-based screening is more effective than cytological screening
in reducing the incidence of invasive squamous and adeno-carcinoma of the cervix uteri [18,
19]. The current prevalence of HPV infection in Swaziland remains unknown. Epidemiologi-
cal data on prevalence, distribution of HPV types and HPV-related conditions are vitally
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important to reduce the burden of CC by (1) guiding the introduction of prophylactic vac-
cines, (2) strengthening the screening programme, (3) promoting the development of cancer
registration, and (4) initiating a national cancer prevention and control policy discussion.
Therefore, the main aim of this study was to estimate prevalence and identify associated
determinants of hr-HPV, including HIV infection among reproductive aged women in
Swaziland.
Materials and Methods
Study setting and population
The study participants were women aged between 15 and 49 years, attending healthcare facili-
ties for routine health care-related services in June–July 2015. All women with a history of pre-
vious or current sexual activity who provided written informed consent were included. The
women were recruited from five healthcare facilities (Mbabane Government, Realign Fitkin
Memorial (RFM), Hlatsikhulu, Sithobela and Siteki Public health unit) within the four political
regions of Swaziland that had fully functioning CC screening services such as VIA and cryo-
therapy (Fig 1).
Sample size
To estimated prevalence of the outcomes of interest, assuming 95% confidence and an accept-
able margin of error of 5%, and maximum variability i.e. 50% (given unknown prevalence) a
sample size of 384 subjects was required were used. The sample was further increased by a
margin of 10% to account for potential non-response and multiplied by a design effect (D) of
1.5. The final sample size of the study was 650 women.
Sampling strategy
The recruitment of participants was done in two sampling stages; firstly women were stratified
by age (seven age-groups) and then sampled using systematic random sampling (every 3rd
woman of those first selected) using the lottery method. The participants were selected from
each site until the calculated sample size was achieved per site.
Data collection
A structured standardized questionnaire was administered by a trained nurse, prior to clinical
examination and specimen collection, to obtain detailed data on socio-demographic character-
istics, sexual, reproductive and gynaecological histories. Prior to clinical examination and
specimen collection, the nurse midwife inspected perineal, vulvar, vaginal and cervical regions
of each woman for evidence of warts, ulcers, discharge, inflammation or tenderness, and
recorded all abnormalities according to the study protocol. Data were entered and stored into
EpiData 3.02 for Windows (The Epi Data Association Odense, Denmark). Each participant
was assigned a unique study identity number that was used to link the questionnaire with the
specimens. Personal information blinded for researchers was kept on site for results feedback
and validation of data.
Specimen collection and Testing
After visual inspection of the vulva, a non-lubricated sterile disposable speculum was inserted
and cervical cells were collected using a sterile cyto-brush by rotating the brush 3-times 360˚
in the cervix (Copan International, Brescia, Italy). The head of the cervical brush was then
eluted in a labeled vial containing Thin Prep Preservcyt Preservation solution to assess the
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presence of hr-HPV and for the Liquid-Based cytology (ThinPrep;Hologic-Cytyc Company,
Marlborough, Mass). After HIV pre-counselling, 4ml of blood were collected in a vacutainer
tube from participants consenting to HIV testing. All specimens were collected and trans-
ported daily to the national laboratory. All tests were performed at the Swaziland Government
National Referral Laboratory, Mbabane.
HPV testing
The HPV-DNA testing was done using the GeneXpert HPV assay (Xpert HPV Assay)
(Cepheid, Sunnyvale, CA, 2014) according to the manufacturer’s protocol. The Xpert HPV
Assay is a qualitative in vitro test for the detection of the E6/E7 region of the viral DNA
genome from hr-HPV in patient specimens. The Xpert HPV test gives results from 6 separate
channels: (i) sample adequacy control (SAC), (ii) P1-HPV16, (iii) P2-HPV18/45, (iv) P3-HPV
31/33/35/52/58, (v) P4-HPV51/59 and (vi) P5-HPV39/68/56/66. An individual specimen can
be positive for more than one probe. For the purpose of our analysis infection, positivity on
one probe only was classified as single group hr-HPV infection (though with the possibility of
multiple HPV type infection with P2-P5). Multiple group hr-HPV infection was classified as
positivity on two or more probes.
Fig 1. Map showing the location, political regions of Swaziland and health facilities (study sites with a red star). Source: Macmillan.
Geography and map of Swaziland Matsapha2005 [accessed 2012 13]. Available from: http://geography.about.com/library/blcswaziland.htm.
doi:10.1371/journal.pone.0170189.g001
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HIV Testing
The Alere Determine HIV-1/2 Ag/Ab Combo test was used to detect both HIV-1/2 antibodies
and free HIV-1 p24 antigen. Reactive specimens were confirmed by Trinity Biotech Uni-Gold
Recombigen HIV Test. All participants who tested HIV-positive were post-counselled and
referred to health units offering the necessary HIV treatment, care and support services.
Data analysis
Data were processed and analysed using Stata 13.0SE (Stata corp.College station, Texas, USA).
Data were checked for possible errors and missing values prior to analysis. Age and region-
weighted analyses were done to estimate the overall hr-HPV prevalence and co-infection with
HIV infection given the stratified systematic random sampling design. Survey weighted Analy-
sis was done to adjust the sample characteristic to match up with the target population (15–49)
that they were selected to represent. It’s applied to bring the proportion of women in the sam-
ple in the alignment with the portion of women in the target population. Therefore all results
reported as weighted. Survey weighted prevalence and 95% confidence interval (CI) were cal-
culated. In addition, assuming that our study subjects are representative of the population of
Swaziland, we used survey weights to extrapolate sample proportions to population totals (age-
region weighted) to estimate burden counts based on the 2007–2030 population projections
aligned to the 2014 population estimates total of 377169 women aged 15–49 years [20]. Differ-
ences in prevalence by categorical variables such as site, age, and HIV were assessed using the
survey weighted chi-squared (χ2) test. Odds ratios (unadjusted and adjusted) and 95%CIs for
potential risk factors associated with hr-HPV were estimated using logistic regression model.
Variables significant at significant cut-off of 0.2 in the bivariate regression analyses were
selected for inclusion into the final multivariable model. An adjusted p-value of<0.05 was
deemed statistically significant.
Ethical consideration
The study was approved by the Swaziland Scientific Ethics Committee (MH599C/FW00015267/
IRB0009688) and the Biomedical Research Ethics Committee of the University of KwaZulu-
Natal (BE 242/14). Ethics committees approved written informed consent which was obtained
from all the participants prior participating to the study. All sexually active women aged between
15 and 49 years attending various reproductive health clinics and other units from all the study
sites, were eligible for the study. In Swaziland according to national guidelines for HIV testing
and counselling, the consenting age is 12 years [21].
Results
Characteristics of the study population
A total of 655 women were enrolled in the study in June–July 2015. A total of 644 subjects pro-
duced sufficient specimen for hr-HPV testing i.e. 11 were thus excluded from further analyses.
The mean (± standard deviation [SD]) age for enrolled women was 32.2 (±8.7) years, and at
menarche 14.4 (±1.7) years, at first intercourse 17.9 (±2.9) years, and at first pregnancy 19.4
(±3.9) years. Of the 644 participants, 571 (88.7%) had been pregnant previously, 542 (84.2%)
had a history of contraceptive use, 272 (42.6%) had a history of STIs, 116 (18.0%) had STIs that
had been treated in the past 12 months, 345 (53.6%) were married or cohabiting, 373(57.9%)
had attended secondary/high school, 340(53.0%) were unemployed and 513(79.7%) reported
one lifetime sexual partner (Table 1).
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Table 1. Socio-demographic characteristics of the study population (N = 644).
Demographics n (%)
Age: n (%)
Mean ± SD (range) 32 .2 ± 8.7
15–19 39 (6.1)
20–24 111 (17.2)
25–29 131 (20.3)
30–34 116 (18.0)
35–39 103 (16.0)
40–44 80 (12.4)
45–49 75 (11.6)
Marital status: n (%)
Single 266 (41.3)
Cohabiting 38 (5.9)
Married 307 (47.7)
Divorced/separated 22 (3.4)
Widow 11 (1.7)
Education: n (%)
Never been to school 24 (3.7)
Primary 130 (20.2)
Secondary/High 373 (57.9)
Tertiary 117 (18.2)
Occupation: n (%)
Unemployed 340 (53.0)
Employed 255 (39.8)
Self-employed 46(7.2)
Pregnant before: n (%)
Yes 571 (88.7)
No 64 (9.9)
Missing 9 (1.4)
Age at first pregnancy: Mean age (SD) 19.4 (3.9)
No. pregnancies: n (%)
0 6 (1.0)
1 139 (24.3)
2 127 (22.2)
3+ 297(46.1)
Age Menarche: Mean (SD) 14.39 (1.7)
Age at first intercourse: Mean age (SD) 17.90 (2.9)
Number of Sexual life partner: n (%)
0 33 (5.1)
1 513 (79.7)
2 61 (9.5)
3+ 43 (6.7)
Contraceptives use: n (%)
Yes 542 (84.2)
No 95 (14.8)
Missing 7 (1.1)
Ever had STI: n (%)
Yes 272 (42.6)
(Continued )
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Hr-HPV prevalence
The overall weighted hr-HPV prevalence was 46.2% (95%CI: 42.8–49.5) (Table 2). Of hr-HPV
infected women, 12.4% (95%CI: 8.6–17.5) were HPV16-positive, 13.8% (95%CI: 12.0–15.8)
were positive for HPV18/45, 26.7% (95%CI: 24.2–29.3) for HPV31/33/35/52/58, 7.6% (95%
CI:7.6–11.9) for HPV51/59 and 11.0%, (95%CI: 7.9–15.3) for HPV39/56/66/68 (Table 2). The
highest peaks of hr-HPV infection were noticed among women younger than 30 years (55.4%
in 15–19 years old, 54.5% in 20–24 years old and 55.8% in 25–29 years old) as compared to
older women (aged between 30 and 49 years). The prevalence declined with increasing age
(Table 3 and Fig 2). The highest hr-HPV prevalence was detected among women from Siteki
PHU (52.8%, 95%CI: 39.5–65.7), although the difference across the sites was not significant
(p = 0.84) (Table 3).
Table 1. (Continued)
Demographics n (%)
No 337 (52.7)
Don’t remember 30 (4.7)
STIs treated in the past 12 months: n (%)
Yes 116 (18.0)
No 520 (80.9)
Don’t know 7 (1.1)
HIV Status: n (%)
Positive 276 (42.7)
Negative 368 (57.1)
doi:10.1371/journal.pone.0170189.t001
Table 2. The weighted prevalence and estimated population burden of hr-HPV infection among sexual reproductive women (15–49 years) in Swa-
ziland (n = 644).
Hr-HPV types Positive
(N = 644)i
Crude prevalence
(%)
Survey weighted prevalence(%,
95%CI)
Population
burdenj
95%CI
All hr-HPV types 273 42.1 46.2 (42.79–49.53) 174046 153294–
194797
HPV16 64 9.7 12.4 (8.61–17.45) 46642 28097–65188
HPV18/45 78 12.0 13.8 (11.95–15.83) 51959 45976–57942
HPV31/33/35/52/ 58 157 24.3 26.7 (24.23–29.27) 100598 86384–114811
HPV51/59 43 6.6 7.6 (4.9–11.91) 28730 16672–40787
HPV39/56/66/68 67 10.3 11.0 (7.86–15.29) 41630 29163–54097
Single group hr-HPV
infectiona
170 26.4 27.4 (24.72–30.21 103260 86550–119970
Multiple group hr-HPV
infectionb
103 16.0 18.8 (15.71–22.27) 70786 58763–82808
i: N = 655 but eleven samples were not valid for HPV testing
j: Population burden estimates to extrapolate absolute burden counts were made based on the 2007–2030 population projections aligned to the 2014
population estimates
a: Single group hr-HPV positivity on one probe only was classified as single group hr-HPV infection (though with the possibility of multiple HPV type infection
with P2-P5).
b: Multiple group hr-HPV infection: classified as positivity on two or more probes.
NB: The totals of HPV types positive do not add up to the total of all hr-HPV types because some have multiples types as grouped by the GeneXpert HPV
assay
doi:10.1371/journal.pone.0170189.t002
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Population burden of hr-HPV
Based on sampling weights, the overall population burden of hr-HPV among women aged
between 15 and 49 years was estimated at 174 046 (95%CI: 153 294–194 797). When stratified
by types 46 642 (95%CI: 28 097–65 188) were estimated to have HPV16, 51 959 (95%CI:
45976–57942) HPV18/45, 100 598 (95%CI: 86 384–114 811) HPV31/33/35/52/58, 28 730 (95%
CI: 16 672–40 787) HPV51/59 and 41 630 (95%CI: 29 163–54 097) HPV39/56/66/68 (Table 2).
Multiple group hr-HPV infection were detected in 18.8% (95%CI: 15.71–22.27) of subjects
while 27.4% (95%CI: 24.72–30.21) were infected with a single group hr-HPV infection
(Table 2). Population burden of single group hr-HPV was estimated at 103 260 women aged
15–49 (95%CI: 86 550–119 970) and 70786 (95%CI: 58 763–82 808) with multiple group hr-
HPV infection (Table 2).
HIV prevalence and Hr-HPV/HIV co-infection
The overall HIV weighted prevalence was 42.7% (95%CI: 35.7–46.2). The HIV prevalence
increased with age; from 24.5% (95%CI: 12.3–42.8) in the 15–19 year age group, to a peak of
Table 3. Overall hr-HPV, HIV and hr-HPV/HIV co-infection prevalence by age groups and study site (Crude and weighted) (N = 644).
Characteristic *Crude hr-HPV+ve
(n, %) (N = 644)
hr-HPV+ve (weighted)
(%, 95%CI)
*Crude HIV+ve (n,
%)(N = 644)
HIV+vej (weighted)
(%, 95%CI)
hr-HPV and HIV co-infection
hr-HPV+ve
only
HIV+ve
only
hr-HPV &
HIV +ve
Age group
15–19 25 (56.8) 55.4 (44.5–65.7) 10 (22.7) 24.5 (12.3–42.8) 37.7 (29.4–
46.8)
6.8 (2.7–
15.9)
17.7 (7.5–
36.4)
20–24 60 (55.6) 54.5 (46.8–61.9) 35 (32.4) 35.2 (26.8–44.7) 26.0 (18.1–
35.9)
6.8 (2.8–
15.5)
28.5 (19.9–
38.9)
25–29 66 (54.1) 55.8 (44.0–66.9) 48 (39.3) 39.0 (34.1–44.2) 27.3 (18.6–
38.2)
10.9 (5.2–
21.6)
28.5 (23.7–
33.9)
30–34 62 (43.7) 44.2 (34.7–54.1) 72 (50.7) 51.4 (44.2–58.6) 14.0 (7.1–
26.1)
21.2 (14.6–
29.9)
30.2 (21.8–
40.4)
35–39 28 (29.8) 31.1 (22.8–40.8) 51 (54.3) 58.1 (40.7–73.7) 6.5 (2.4–
16.5)
33.6 (25.9–
42.2)
24.6 (15.8–
36.0)
40–44 20 (26.3) 30.0 (21.8–39.7) 36 (47.4) 51.3 (36.6–65.8) 7.5 (3.2–
16.6)
27.0 (19.8–
35.5)
22.5 (11.4–
39.8)
45–49 12 (20.7) 20.59 (42.5–49.4) 24 (41.4) 44.0 (27.3–62.2) 6.2 (2.7–
13.9)
29.6 (13.6–
53.0)
14.4 (7.7–
25.2)
Study Sites
Mbabane (H01) 78 (43.8) 45.5 (32.4–59.2) 68 (38.2) 33.2 (22.4–46.0) 25.3 (17.3–
35.3)
13.4 (04.8–
32.0)
19.6 (16.4–
23.3)
RFM (H02) 76 (39.6) 40.7 (35.2–46.5) 96 (50.0) 44.3 (27.4–62.6) 15.3 (0.7–
31.9)
19.2 (11.9–
29.5)
25.0 (15.8–
37.3)
Siteki PHU
(H03)
34 (50) 52.8 (39.5–65.7) 31 (45.6) 41.3 (21.8–64.0) 28.0 (13.3–
49.7)
16.5 (0.9–
28.8)
24.8 (13.0–
42.1)
Sithobela (H04) 30 (44.8) 49.1 (32.1–66.4) 32 (47.8) 45.3 (31.4–60.0) 20.0 (0.9–
38.3)
16.1 (0.5–
40.9)
29.1 (18.9–
42.1)
Hlathikhulu
(H05)
55 (39.6) 47.4 (31.1 –- 64.0) 49 (35.3) 39.0 (30.9–47.8) 22.3 (12.1–
37.4)
13.9 (0.8–
23.7)
25.1 (20.4–
30.5)
Overall 273 (42.4) 46.2 (42.5–49.4) 276 (42.9) 42.7 (35.7–46.2) 21.5 (17.7–
25.9)
16.1 (12.9–
19.9)
24.4 (20.5–
28.7)
iHIV+ve: HIV-positive
jhr-HPV+ve: hr-HPV-positive
*crude: The prevalence based on the study sample size (N = 644).
doi:10.1371/journal.pone.0170189.t003
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58.1% (95%CI: 40.7–73.7) in the 30–34 year age group, and then declined in the 45–49 year
age group (44.0%; 95%CI: 27.3–62.2) (Table 3). The overall hr-HPV/HIV co-infection was
24.4% (95%CI: 20.5–28.7) and it was significantly higher among the young age groups than the
older age groups (p<0.001) (Table 3). While hr-HPV prevalence significantly decreased with
age, HIV prevalence significantly increased with age (p<0.001) (Fig 2). The age-specific preva-
lence for hr-HPV/HIV co-infection was significantly high among the 20–30 age group with
the highest peak among the 30–34 age group and declined in older age groups (p<0.001) (Fig
3). Age-specific prevalence of Hr-HPV among reproductive aged women who were HIV-posi-
tive was significantly higher as compared to HIV-negative women (78% in the 15–19 age, 80%
in the 20–24 age, 72% in the 25–29 age and 58% in the 30–34 age) (S1 Fig). Also, the prevalence
of multiple group hr-HPV types was significantly higher in HIV-positive women (27.7%, 95%
CI: 22.6–33.6) compared to HIV-negative women (12.7%, 95%CI: 15.7–22.3) (p<0.001) (data
not shown). HPV16 and HPV31/33/35/52/58 were significantly higher among HIV-positive
women as compared to HIV-negative women (17.6%, OR = 2.2, 95%CI: 1.1–4.5, p = 0.029,
and 40.4%, OR = 3.2, 95% CI: 1.9–5.5, p <0.001, respectively) (S1 Table).
Fig 2. Age-specific prevalence of HPV and HIV among reproductive age women in Swaziland.
doi:10.1371/journal.pone.0170189.g002
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Risk factors associated with hr-HPV infection
Table 4 shows risk factors associated with hr-HPV infection. Based on the univariate analysis:
increasing age (OR = 0.94, 95%CI: 0.93–0.96, p<0.001), being married (OR = 0.6, 95%CI: 0.4–
0.8, p = 0.003) and increasing number of pregnancies (OR = 0.9, 95%CI: 0.8–0.9, p = 0.001)
were inversely associated with hr-HPV. Only HIV-positive status was positively associated
with hr-HPV (OR = 2.9, 95%CI: 2.1–4.0), p<0.001). Even after multivariable adjustment, the
risk of hr-HPV decreased with increasing age (OR = 0.9, 95%CI: 0.92–0.94, p<0.001). Those
living with partners had a decreased risk of being hr-HPV infected (OR = 0.4, 95%CI, 0.2–0.9,
p = 0.027), and being HIV-positive remained a highly prominent risk factor for hr-HPV infec-
tion (OR = 4.1, 95%CI: 2.8–6.0, p<0.001). The presence, absence or unknown of history of STI
with HIV did not appear to modify the relationship with hr-HPV (OR = 4.2, 95%CI: 2.6–7.1,
OR = 4.6, 95%CI: 2.8–7.7, p<0.001, p<0.001 and OR = 4.1, 95%CI: 1.3–13.4, p<0.021
respectively).
Education status, parity, age at first sexual encounter and history of STIs treated in the past
12 months were not associated with hr-HPV after multivariable adjustment.
Fig 3. The trend of hr-HPV types and HIV infection by age-group.
doi:10.1371/journal.pone.0170189.g003
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Table 4. Risk factors associated with hr-HPV infection (N = 644).
Risk factors hr-HPV+ve Unadjusted (univariate) Adjusted
(multivariable)i
n/N (%) OR (95%CI) P-value OR (95%CI) P-value
Age
Mean ± SD (range) 273/
644
42.4 0.94 (0.93–
0.96)
<0.001 0.92 (0.90–
0.94)
<0.001
Marital status
Single 132/
266
49.6 1 (ref) 1 (ref)
Living with partner/Cohabiting 13/38 34.2 0.5 (0.3–1.1) 0.079 0.4 (0.2–0.9) 0.027
Married 115/
307
37.5 0.6 (0.4–0.8) 0.003 1.0 (0.7–1.5) 0.982
Divorced/separated 9/22 40.9 0.7 (0.3–1.7) 0.434 1.3 (0.5–3.7) 0.562
Widow 4/11 36.4 0.6 (0.2–2) 0.394 1.5 (0.4–5.9) 0.607
Education
Never been to school 10/24 41.7 1 (ref)
Primary 60/130 46.2 1.2 (0.5–2.9) 0.685
Secondary/High 153/
373
41.0 1 (0.4–2.2) 0.95
Tertiary 50/117 42.7 1 (0.4–2.5) 0.923
Occupation
Unemployed 153/
340
45.0 1 (ref) 1 (ref)
Employed 104/
255
40.8 0.8 (0.6–1.2) 0.304 1.2 (0.82–
1.75)
0.355
Self-employed 15/46 32.6 0.6 (0.3–1.1) 0.115 0.64 (0.3–
1.35)
0.239
Pregnant before
Yes 239/
571
41.9 1 (ref)
No 31/64 48.4 1.3 (0.8–2.2) 0.314
No. of pregnancies (Mean) 273/
644
42.4 0.9 (0.8–0.9)* 0.001*
Age Menarche (Mean age) 273/
644
42.4 1.1 (1–1.2) 0.13
Age at first sex (mean age) 273/
644
42.4 1 (1–1.1) 0.654
Sexual life partner
0 11/33 33.3 1 (ref) 1 (ref)
1 214/
513
41.7 1.4 (0.7–3) 0.345 0.94 (0.4–
2.21)
0.883
2 31/61 50.8 2.1 (0.9–5) 0.106 1.04 (0.38–
2.85)
0.938
3+ 17/36 47.2 1.8 (0.7–4.7) 0.242 0.95 (0.31–
2.88)
0.924
Contraceptives use
Yes 225/
542
41.5 1 (ref)
No 44/95 46.3 1.2 (0.8–1.9) 0.382
Ever had STI
Yes 113/
272
41.5 1 (ref)
(Continued )
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Discussion
This is the first study assessing prevalence of and risk factors for hr-HPV infection in Swazi-
land, a country severely affected by the HIV epidemic. The present study shows a high preva-
lence of hr-HPV infection (46.2%), corresponding to 174,046 women (aged between 15 and 49
years old) with hr-HPV in Swaziland. Differences were observed regarding the HPV types,
whereHPV31/33/35/52/58 group types had the highest frequency (26.7%) among the study
population. Among the same population, high prevalence of HIV (42.7%) was found. The age-
specific prevalence of hr-HPV significantly decreased with age, yet HIV prevalence increased
with age and slightly declined in the 45–49 year age group. The hr-HPV/HIV co-infection was
24.4%, with a high peak in the 30s and decline in older groups. The prevalence of multiple hr-
HPV infections was statistically significantly higher among HIV-positive women (27.7%)
when compared with HIV-negative women. In our sensitivity analysis HPV16 and HPV31/33/
35/52/58 types were significantly higher among HIV-positive women when compared to HIV-
negative women. Multivariate analysis showed that HIV status was the strongest risk for hr-
HPV infection (OR = 4.9). Also the risk of being infected with hr-HPV infection decreased
with increasing age (OR = 0.92), and being married (OR = 0.4).
The key strength of our study was that primary data and new specimens were used to ascer-
tain the study outcomes. Being the first hr-HPV study done in the country we were able to
extrapolate population totals of the 15–49 age group from the 2007–2030 population
Table 4. (Continued)
Risk factors hr-HPV+ve Unadjusted (univariate) Adjusted
(multivariable)i
n/N (%) OR (95%CI) P-value OR (95%CI) P-value
No 142/
337
42.1 1 (0.7–1.4) 0.883
Don’t remember 16/30 53.3 1.6 (0.8–3.4) 0.219
STIs treated in the past 12 months
Yes 53/116 45.7 1 (ref)
No 214/
520
41.2 0.8 (0.6–1.2) 0.371
Don’t know 5/7 71.4 3 (0.6–15.9) 0.204
HIV Status
Negative 116/
368
31.5 1 (ref)
Positive 157/
276
56.9 2.9 (2.1–4) <0.001 4.1 (2.8–6.0) <0.001
Interaction between HIV and ever had other STI (0 = negative, 1 = positive,
9 = unknown)
0 0 68/211 1 (ref)
0 1 39/139 1.0 (0.6–1.7) 0.949
0 9 7/15 2.1 (0.7–6.4) 0.201
1 0 74/126 4.6 (2.8–7.7) <0.001
1 1 74/133 4.2 (2.6–7.1) <0.001
1 9 9/15 4.1 (1.3–13.4) 0.020
iAdjusted Odds Ratio for age marital status, level of education, occupation, history of pregnancy, age at first sex, history of STIs, STIs treated in the past 12
months, HIV status;
* negatively confounded by age, after adjustment for age this was no longer statistically significant and hence not retained in the final multivariable model
doi:10.1371/journal.pone.0170189.t004
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projections aligned to the 2014 population estimates [20] to estimate the population burden of
hr-HPV infection and weighted hr-HPV infection in this population. This was done because
our study population was age-stratified and we needed to adjust sample characteristics to
match up with the target population (15–49 years) that they were selected to represent. Fur-
thermore, since we had seven age-groups in our sample with various numbers of participants,
we assigned various weights (age and region) to the response, to improve our ability to extrap-
olate results which were as interpretable as possible. This was done to prevent unequal counts
or skewed results. The study was done in Swaziland among normal women population. The
women were asymptomatically or did not have any symptoms that could have led to selection
bias. An important limitation is the lack of genotyping of all the HPV types including low-risk
types circulating within the population. We can currently only generalize the results among
the population of age 15–49 years in Swaziland. In addition, since our study subjects were
recruited from hospitals, they may not be truly representative of the general population which
could introduce selection bias. However, weighting was applied when reporting summary
results for the whole study sample.
Our study shows a high overall prevalence of hr-HPV infection, with the highest among the
younger age groups. These findings are consistent with previous studies reporting high HPV
prevalence in the population of sub-Saharan Africa, Asia and Latin America [22–27]. A study
done in South Africa demonstrated a hr-HPV prevalence of 44.9% among women without
cytological abnormalities [27]. Studies conducted in Tanzania and Nigeria found high preva-
lence of HPV (20.1% and 14.7% respectively) [23, 25]. In China the prevalence of HPV infec-
tion was found to vary between regions from 13.8%–44.4% [28]. A higher prevalence of above
75% was observed in two studies conducted in Brazil [22, 26]. Furthermore, the prevalence
found in this study is higher than that of the sub-Saharan Africa region (SSA) (24.0%) [10].
HPV prevalence is highest among women <25 years old with a rapid fall among women in
their 30s and 40s [27]. As highlighted in two large meta-analyses of HPV prevalence studies in
LICs [4, 24], the prevalence of HPV and hr-HPV in both groups was highest among young
women with a steady decline until the age group of 45–49. Our study concurs with such find-
ings where the age-specific prevalence was significantly high among the ages of 15–30 and
declined with age. According to Winer and colleagues, the actual first peak of HPV infection
might be before the age of 25 years, as women are usually infected after sexual initiation [29].
HPV16 and 18 types have been found to be the most prevalent high risk types in most studies
[4, 26–28, 30–32], yet in the current study we were not able to establish that. However, we
observed high frequency of hr-HPV31/33/35/52/58 group types among the study population.
Therefore, we cannot draw conclusions as to which is the most common genotype within the
groups detected because the Xpert-HPV test gives results from six separate channels and the
lack of genotyping. However, the current study has provided background knowledge about the
distribution of hr-HPV in the Swazi women population. Such information is crucial to guide
the introduction of prophylactic vaccine, as the country is working towards achieving such a
goal. Furthermore, HPV screening seems to promote earlier identification of women at high
risk of CC.
In relation to screening, the main problem is that if the country decided to do, for example,
HPV and treat this group they would be treating 40% of the 30–34 age group and 30% of the
35–44 age group, which is much more than what has been done in other places. In this context
the country would definitely require a triage method or a reduction in the number of hr-HPV
types included for primary screening. The high frequency of types rarely seen in cancer is par-
ticularly important.
In this study, HIV weighted prevalence was very high among the study population (42.7%)
and there was a high prevalence in the 25–29, 30–34 and 35–39 age groups, (34.1%, 44.2%,
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40.7% respectively). The increase in the prevalence of HIV as age increases has been reported
in different surveys [33, 34]. The current study demonstrated the high HPV/HIV co-infection
of 24.4%, with high hr-HPV prevalence across almost all age groups and more multiple hr-
HPV infection in HIV-positive women than compared to HIV-negative women. These find-
ings are consistent with previous studies reporting higher prevalence of HPV [9, 27, 30, 35]
and higher frequency of infection with multiple HPV types among HIV infected women [30,
32, 36]. A number of risk factors for HPV infection among women have been demonstrated in
previous studies, including having more than one partner, early sexual initiation, age and mar-
ital status. In the multivariate adjusted model, age was the variable with a strong inverse associ-
ated with HPV risk, which might be due to the fact that most young women get infected after
sexual initiation [29] and exposure is reduced or immunity develops with increasing age.
Based on our findings, the risk of hr-HPV infection decreased with increasing age. Therefore,
older women were less likely to have hr-HPV infection. Such inverse association with age has
been shown in numerous other studies [37–39]. After adjusting for all the possible socio-
demographic and reproductive confounders, women living with partners were less likely to be
infected with HPV infection than compared to single women. Our results are consistent with
other studies, where women who were not married or living with a partner had a higher risk of
HPV infection [40, 41].
Studies have demonstrated unemployment as significant driver for the increased STIs
among women and it’s associated with significantly higher odds of STIs [42, 43]. However, our
study has found contrasting findings where by significant association between employment
status and hr-HPV infection was not established. This might be due to the fact that financial
independent woman have the ability to provide financial and material resources for themselves
even if they are in a relationship. Furthermore, such ability can give them power to make
sound decisions about engaging in protected sex when compared to unemployed women.
According to Muula, unemployment may leave women with limited alternatives where they
may resort to engaging in high risk behaviour such as becoming sex workers or engaging in
transactional sex in which they provide sex in exchange for money and material resources
from a partner [44].
A vital clinical and public health consequence of our findings is that HIV was the strongest
risk factor associated with hr-HPV infection. HIV-positive women are approximately 5 times
more likely to be infected with hr-HPV infection. Additional, overall infection and specifically
HPV16 and HPV31/33/35/52/58 were significantly more common among HIV-positive
women as compare to HIV-negative women in our study. The strong association between
HIV and HPV infection has been demonstrated in several previous studies [38, 45, 46]. The
increased risk of HPV infection in HIV patients has been associated with impaired immune
response to HPV [46]. On the other hand, HPV-DNA has been established to be at a level of
6–18 times more likely to persist among HIV-infected women than compared to HIV-negative
women [47]. HIV affects the immune system, making individuals more susceptible to HPV
infection, and less likely to clear their HPV infection [47, 48]. These findings are significantly
important for polices with a focus on HIV infected women to prevent HPV infection, cervical
lesions and CC.
We further assessed the interaction between HIV and history of STIs with hr-HPV. Our
study found that the presence, absence or unknown of history of STI with HIV did not appear
to modify the relationship with hr-HPV infection. To our knowledge no much studies that
have assessed the interaction between HIV and history of STIs with hr-HPV. However, there
is an evidence that STIs or having had STI 12months before increases the probability of HIV
including HPV infection [49, 50].
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Factors such as educational status, history of pregnancy, number of pregnancies, age at first
sexual encounter, age at menarche, number of sexual partners, contraceptives use, history of
STIs and history of STIs treated in these past 12 months were not associated with HPV infec-
tion in our study, although in other studies, the factors were strongly associated with among
population at risk HPV infection [31, 40, 51, 52]. The explanation of such inconsistency may
indicate the role of high risk partners.
In conclusion, the prevalence of hr-HPV is high among women of reproductive age in Swa-
ziland. HIV prevalence among reproductive aged women remains high in the country. The
study confirms the high HPV/HIV co-infection rate and the high correlation between hr-HPV
and HIV infection observed in previous studies. In addition, HPV infection was significantly
common among HIV-positive women as compared to HIV-negative women in all age groups.
The prevalence of multiple hr-HPV infections was significantly high among HIV-positive
women compared to HIV-negative women. Furthermore, the study has provided essential
information about the HIV link with HPV infections which may explain the high incidence.
This can contribute to policy development and planning of prevention strategies incorporating
HPV infection prevention especially among the youth and HIV infected people. Furthermore,
our findings support the suggestion of comprehensive screening approaches incorporating hr-
HPV testing with the existing screening programme, must be considered with triage modali-
ties other than cytology. Finally, our findings provide epidemiological knowledge about the
distribution of hr-HPV. This is crucial to guide the future introduction of prophylactic vaccine
in Swaziland.
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